MA33834B1 - Formulation contenant des antagonistes du récepteur ampa à base de 1h-quinazoline-2,4-dione, sous la forme de comprimés à libération immédiate et leur préparation - Google Patents
Formulation contenant des antagonistes du récepteur ampa à base de 1h-quinazoline-2,4-dione, sous la forme de comprimés à libération immédiate et leur préparationInfo
- Publication number
- MA33834B1 MA33834B1 MA34983A MA34983A MA33834B1 MA 33834 B1 MA33834 B1 MA 33834B1 MA 34983 A MA34983 A MA 34983A MA 34983 A MA34983 A MA 34983A MA 33834 B1 MA33834 B1 MA 33834B1
- Authority
- MA
- Morocco
- Prior art keywords
- substituents
- group
- chosen
- amino
- dialkylamino
- Prior art date
Links
- SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 title 1
- 229940098747 AMPA receptor antagonist Drugs 0.000 title 1
- 239000000775 AMPA receptor antagonist Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 4
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 4
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 3
- -1 cyano, hydroxy Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000004442 acylamino group Chemical group 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 abstract 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 abstract 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un comprimé contenant une hydroxypropylcellulose et un principe actif choisi parmi des composés de formule (i) et leurs sels : où r1 représente un groupe cf3, chf2, ch2f, ch3chf-, ch3cf2-, éthyle ou iso-propyle et r2 représente un groupe alkyle substitué par un ou plusieurs substituants, les substituants étant choisis dans le groupe comprenant les atomes d'halogène, les groupes nitro, cyano, acyle, hydroxy, oxo (=o), alcoxy, cycloalcoxy, acyloxy, alcoxycarbonyloxy, amino, alkylamino, dialkylamino, formyle, acylamino, alcoxycarbonylamino ou r2 représente un groupe hétérocyclylalkyle substitué par un ou plusieurs substituants, les substituants étant choisis dans le groupe comprenant les atomes d'halogène, les groupes nitro, cyano, hydroxy, alcoxy, alkylcarbonyloxy, alcoxycarbonyloxy, amino, alkylamino, dialkylamino, alcoxycarbonylamino, ou r2 représente un groupe phényle substitué par un ou plusieurs substituants, les substituants étant choisis dans le groupe comprenant les groupes cyano, hydroxy, alcanediyle, alcènediyle, alcoxy, hydroxyalkyle, formyle, alkylcarbonyle, alcoxycarbonyle, alkylcarbonyloxy, alcoxycarbonyloxy, amino, alkylamino, dialkylamino, aminoalkyle, alkylaminoalkyle, dialkylaminoalkyle, alcoxycarbonylamino, ou r2 représente un groupe hétérocyclyle éventuellement substitué par un ou plusieurs substituants, les substituants étant choisis dans le groupe comprenant les atomes d'halogène, les groupes hydroxy, amino, nitro, cyano, alkyle, hydroxyalkyle, alcoxyalkyle, aminoalkyle, alkylaminoalkyle, dialkylaminoalkyle, acyle, alcoxy, acyloxy, alcoxycarbonyloxy, amino, alkylamino, dialkylamino, acylamino, alcoxycarbonylamino et l'hétérocycle étant lié au cycle phényle par un atome de carbone. L'invention a également pour objet un procédé de préparation du comprimé ci-dessus.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28898509P | 2009-12-22 | 2009-12-22 | |
| PCT/US2010/061553 WO2011079119A1 (fr) | 2009-12-22 | 2010-12-21 | Formulation contenant des antagonistes du récepteur ampa à base de 1h-quinazoline-2,4-dione, sous la forme de comprimés à libération immédiate et leur préparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33834B1 true MA33834B1 (fr) | 2012-12-03 |
Family
ID=43610748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34983A MA33834B1 (fr) | 2009-12-22 | 2012-06-18 | Formulation contenant des antagonistes du récepteur ampa à base de 1h-quinazoline-2,4-dione, sous la forme de comprimés à libération immédiate et leur préparation |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20120263791A1 (fr) |
| EP (1) | EP2515873A1 (fr) |
| JP (1) | JP2013515076A (fr) |
| KR (1) | KR20120105035A (fr) |
| CN (2) | CN104013587A (fr) |
| AU (1) | AU2010336510B2 (fr) |
| BR (1) | BR112012016920A2 (fr) |
| CA (1) | CA2784996A1 (fr) |
| CL (1) | CL2012001689A1 (fr) |
| EC (1) | ECSP12011994A (fr) |
| GT (1) | GT201200209A (fr) |
| MA (1) | MA33834B1 (fr) |
| MX (1) | MX2012007320A (fr) |
| NZ (1) | NZ600717A (fr) |
| PE (1) | PE20121394A1 (fr) |
| PH (1) | PH12012501289A1 (fr) |
| RU (1) | RU2012131051A (fr) |
| SG (1) | SG181787A1 (fr) |
| WO (1) | WO2011079119A1 (fr) |
| ZA (1) | ZA201204607B (fr) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2465693A1 (fr) * | 2003-06-12 | 2004-12-12 | Warner-Lambert Company Llc | Compositions pharmaceutiques d'atorvastatine |
| GB0416730D0 (en) * | 2004-07-27 | 2004-09-01 | Novartis Ag | Organic compounds |
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| WO2006110811A1 (fr) * | 2005-04-12 | 2006-10-19 | Elan Pharma International Limited | Formules de nanoparticules de derives de quinazoline |
| JOP20180109A1 (ar) * | 2005-09-29 | 2019-01-30 | Novartis Ag | تركيبة جديدة |
| EP1968553A2 (fr) * | 2005-11-09 | 2008-09-17 | Novartis AG | Procede de fabrication de compositions pharmaceutiques utilisant un plastifiant transitoire |
| US8673353B2 (en) * | 2008-02-11 | 2014-03-18 | Dainippon Sumitomo Pharma Co., Ltd | Tablet having improved elution properties |
-
2010
- 2010-12-21 MX MX2012007320A patent/MX2012007320A/es not_active Application Discontinuation
- 2010-12-21 CN CN201310590709.7A patent/CN104013587A/zh active Pending
- 2010-12-21 PE PE2012000861A patent/PE20121394A1/es not_active Application Discontinuation
- 2010-12-21 JP JP2012546151A patent/JP2013515076A/ja active Pending
- 2010-12-21 NZ NZ600717A patent/NZ600717A/en not_active IP Right Cessation
- 2010-12-21 RU RU2012131051/15A patent/RU2012131051A/ru not_active Application Discontinuation
- 2010-12-21 US US13/518,027 patent/US20120263791A1/en not_active Abandoned
- 2010-12-21 AU AU2010336510A patent/AU2010336510B2/en not_active Expired - Fee Related
- 2010-12-21 CA CA2784996A patent/CA2784996A1/fr not_active Abandoned
- 2010-12-21 KR KR1020127019189A patent/KR20120105035A/ko not_active Withdrawn
- 2010-12-21 CN CN2010800643985A patent/CN102770124A/zh active Pending
- 2010-12-21 PH PH1/2012/501289A patent/PH12012501289A1/en unknown
- 2010-12-21 EP EP10803319A patent/EP2515873A1/fr not_active Withdrawn
- 2010-12-21 WO PCT/US2010/061553 patent/WO2011079119A1/fr not_active Ceased
- 2010-12-21 SG SG2012044905A patent/SG181787A1/en unknown
- 2010-12-21 BR BR112012016920A patent/BR112012016920A2/pt not_active IP Right Cessation
-
2012
- 2012-06-18 MA MA34983A patent/MA33834B1/fr unknown
- 2012-06-21 ZA ZA2012/04607A patent/ZA201204607B/en unknown
- 2012-06-21 EC ECSP12011994 patent/ECSP12011994A/es unknown
- 2012-06-21 CL CL2012001689A patent/CL2012001689A1/es unknown
- 2012-06-22 GT GT201200209A patent/GT201200209A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2784996A1 (fr) | 2011-06-30 |
| EP2515873A1 (fr) | 2012-10-31 |
| MX2012007320A (es) | 2012-07-20 |
| BR112012016920A2 (pt) | 2016-04-12 |
| ECSP12011994A (es) | 2012-07-31 |
| SG181787A1 (en) | 2012-07-30 |
| GT201200209A (es) | 2013-09-09 |
| AU2010336510B2 (en) | 2014-06-26 |
| WO2011079119A1 (fr) | 2011-06-30 |
| RU2012131051A (ru) | 2014-01-27 |
| CN104013587A (zh) | 2014-09-03 |
| KR20120105035A (ko) | 2012-09-24 |
| PH12012501289A1 (en) | 2013-01-07 |
| PE20121394A1 (es) | 2012-10-29 |
| JP2013515076A (ja) | 2013-05-02 |
| AU2010336510A1 (en) | 2012-07-12 |
| CN102770124A (zh) | 2012-11-07 |
| NZ600717A (en) | 2014-06-27 |
| ZA201204607B (en) | 2013-02-27 |
| US20120263791A1 (en) | 2012-10-18 |
| CL2012001689A1 (es) | 2013-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55890B1 (fr) | Modulateurs de thr-beta avec un groupe de tête dioxo-1,2,4-triazyl | |
| PE20130385A1 (es) | Derivados del acido naft-2-ilacetico para tratar el sida | |
| MA38138A1 (fr) | Dérivés inédits de quinolone | |
| MA45222A (fr) | Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| CA2536136A1 (fr) | Imidazoquinolines substituees par aryloxy et arylalkyleneoxy | |
| MA37405A1 (fr) | Composés hétérocyclyle | |
| KR910006218A (ko) | 2-아미도테트라린 치환유도체와 이 치환유도체를 포함하는 제약학적 조성물 및 이를 사용한 치료방법 | |
| MA37891B1 (fr) | Alcoxypyrazoles comme activateurs de guanylate cyclase soluble | |
| EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
| JP2972377B2 (ja) | カテコール誘導体、その薬学的に許容しうる塩およびエステルならびにそれらを含有する医薬組成物 | |
| RU2010126105A (ru) | Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащие их противогрибковые средства | |
| JP2018500388A (ja) | 代謝疾患及び癌の治療のための、新規ミトコンドリアアンカップラー | |
| IE83426B1 (en) | New pharmacologically active catechol derivatives | |
| MA31674B1 (fr) | Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique | |
| MA32057B1 (fr) | Derives d'imtoazo [1,2-a] pyridine-2-carboxamides,leur préparation et leur application en thérapeutique | |
| TN2010000025A1 (fr) | Derives de l'indol -2-one disubstitues en 3, leur preparation et leur application en therapeutique | |
| TN2015000240A1 (fr) | Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments | |
| RU2011131276A (ru) | 1н-хиназолин-2,4-дионы | |
| RU2012126112A (ru) | Соединение, некоторые его новые формы, фармацевтические композиции на его основе и способы получения и применения | |
| AU2016214283A1 (en) | Compounds with anti-tumoral activity | |
| AU2014413483A1 (en) | 7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs | |
| WO2006064375A9 (fr) | Composes heterocycliques a noyau a cinq elements a substitution aminoaryle pour le traitement de maladies | |
| RU2010143586A (ru) | Новое производное тетрагидроизохинолина | |
| MA29961B1 (fr) | Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique | |
| MA33834B1 (fr) | Formulation contenant des antagonistes du récepteur ampa à base de 1h-quinazoline-2,4-dione, sous la forme de comprimés à libération immédiate et leur préparation |